Optimizing PARP Inhibitor Outcomes in Cancer Therapy: Focus on Biomarkers of Homologous Recombination Repair
ACPE Activity Number: 0204-0000-23-408-H01-P
Content Release Date: February 8, 2024
Expiration Date: February 8, 2025
Activity Type: Application-based
CE Credits: 1.5 contact hours (0.15 CEUs)
Activity Fee: Free
Activity Overview
The rapid pace in the evolution of knowledge regarding how cancer develops and best approaches to treatment pose challenges to the medical community. This educational activity will review the deleterious effects of DNA damage, specifically the science of homologous recombination deficiency, and how it contributes to the development of cancer. Approved and expanded indications for the PARP inhibitors will be explained, including evidence for their use based on biomarkers, efficacy, and safety data. The activity will include real-life case scenarios demonstrating how genetic testing data can be used to develop treatment plans that illustrate these concepts.
*Please note, this activity was presented live on December 4, 2023 as part of the ASHP 2023 Midyear Clinical Meeting & Exhibition. You can only claim credit once for this activity; live or home study
More in this Series:
Accreditation
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
The target audience for these educational activities is pharmacists, physicians, physician assistants, and nurse practitioners who practice in hospitals and health systems.
Learning Objectives
After participating in this CPE activity, learners should be able to:
- Discuss the mechanisms of homologous recombination deficiency as they relate to the development of cancer.
- Apply evidence-based recommendations in parallel with genomic/molecular diagnostic testing results that inform the use of PARP inhibitors in treating cancer.
- Develop an interprofessional treatment plan taking into account patient-specific and cancer-specific factors, including biomarker testing data.
Faculty
Christine M. Walko, PharmD, FCCP, BCOP
Senior Member, Department of Pathology, Precision Medicine Team Lead
Moffitt Cancer Center
Tampa, Florida
Christine M. Walko graduated with her Pharm.D. degree from Duquesne University in Pittsburgh, Pennsylvania, and completed a pharmacy practice residency at the Medical College of Virginia/VCU in Richmond, Virginia, and a hematology/oncology specialty residency at the University of North Carolina (UNC). She stayed at UNC to complete a 2-year academic oncology fellowship focused on drug metabolism and translational research before taking an Assistant Professor position at UNC in the Division of Pharmacotherapy and Experimental Therapeutics until being recruited to Moffitt Cancer Center in January 2014 to assist with starting the institution’s first Precision Medicine Program. Dr. Walko is now a Senior Member in the Department of Pathology at Moffitt Cancer Center, Program Leader for Precision Medicine and an Attending on the Precision Medicine Clinical Service. She is also a Co-Chair for the ASCO TAPUR trial Molecular Tumor Board (MTB) and variant expert for the nationwide SWOG Precision Medicine trial focused on the clinical utility of Molecular Tumor Boards in Community Oncology Practices. Her research focus is on optimizing drug therapy using pharmacogenomics and pharmacokinetics to personalize intravenous and oral anticancer therapy for patients with cancer.
Jeannie Chern, MD, ScM
Associate Member, Gynecologic Oncologist
H. Lee Moffitt Cancer Center
Associate Professor, Gynecologic Oncologist
University of South Florida Morsani College of Medicine
Tampa, Florida
Dr. Chern is an Associate Member in Gynecologic Oncology at Moffitt Cancer Center. She completed Residency in Obstetrics and Gynecology at the University of South Florida and Gynecologic Oncology Fellowship at New York University. She is the lead for genetics education and tumor board. In addition, she is the assistant program director for the GYN oncology fellowship. Her clinical focus is personalization and comprehensive care for women with gynecologic cancers, with a special interest in the surgical management of advanced malignancies. Dr. Chern’s research is involved in understanding genetic factors associated with gynecologic malignancies to improve and guide patient care.
Jeffery S. Vender, MD, MCCM, MBA is the Emeritus, Harris Family Foundation Chairman of the Department of Anesthesiology at NorthShore University Health System in Evanston, Illinois and a Clinical Professor at the University of Chicago Pritzker School Of Medicine in Chicago, Illinois. He is a past member of the NorthShore University Health System Faculty Practice Associates Board of Directors, Past Chair of the Medical Executive Committee for the Professional Staff at NorthShore and previously served on Northshore’s Board of Directors. Dr. Vender served as Chair of Anesthesia from 1990-2015 and received an appointment of adjunct Professor of Biomedical Engineering at Northwestern University. He served as the Director of the Critical Care Services at Evanston Hospital from 1987-2000 and the Interim Chairman at Northwestern University Department of Anesthesiology from July 1999 until October 2000. Dr. Vender has participated and Chaired numerous state and national committees of various medical organizations, edited several medical texts, has published over 135 articles and book chapters and has been an invited lecturer at over 250 national and international meetings on topics of anesthesiology, critical care, organizational change, and leadership. In addition, Dr. Vender serves as an editor and/or reviewer for many medical journals.
Relevant Financial Relationship Disclosures
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
- Jeannie Chern – AstraZeneca – Consultant, Advisor, and Speaker’s bureau, Baxter – Consultant, Equinox – Consultant, GSK – Advisory Board, Zentalis – Principal Investigator
All other persons in control of content do not have any relevant financial relationships with an ineligible company.
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.
Methods and CE Requirements
To receive CE credit, complete the steps below within 60 days of completing the activity.
- View the entire presentation and answer all polling questions.
- Click "Complete Activity" on last slide then complete the evaluation to claim credit.
- Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.
Important Note – ACPE 60 Day Deadline
Provided by ASHP
Supported by an educational grant from AstraZeneca. Supported by an educational grant from Merck.